Orchid Pharma Ltd

Orchid Pharma Ltd’s shares declined to a fresh 52-week low of Rs.488.8 on 9 March 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed its sector and broader market indices, reflecting persistent pressures on its financial and operational metrics.

Orchid Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 Feb 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Orchid Pharma Ltd experienced a significant intraday decline on 4 Mar 2026, touching a low of Rs 550, reflecting an 8.3% drop from previous levels. The stock underperformed its sector and broader market indices, continuing a downward trend amid persistent selling pressure and subdued market sentiment.

Orchid Pharma Ltd commenced trading today with a significant gap down, opening at an 18.85% lower price compared to its previous close, reflecting heightened market apprehension following recent developments. The stock hit a new 52-week low of Rs.503, underperforming its sector and broader indices amid sustained selling pressure.

Orchid Pharma Ltd’s shares touched a fresh 52-week low of Rs.503 today, marking a significant decline amid ongoing pressures in the Pharmaceuticals & Biotechnology sector. The stock has underperformed both its sector and the broader market, reflecting persistent challenges in financial performance and valuation metrics.

Orchid Pharma Ltd has witnessed a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating, reflecting a subtle but significant change in price attractiveness. Despite this adjustment, the stock remains priced at a premium relative to its peers and historical averages, raising concerns for investors amid a challenging pharmaceutical sector backdrop.

Orchid Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Orchid Pharma Ltd’s share price continues to reflect mounting bearish momentum as multiple technical indicators signal a deteriorating outlook. With the company’s MarketsMOJO grade downgraded to Strong Sell and a notable decline in returns relative to the Sensex, investors are urged to carefully assess the evolving technical landscape before considering exposure to this pharmaceuticals & biotechnology stock.

Orchid Pharma Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average, signalling a potential shift towards a bearish trend. This development highlights a deterioration in the stock’s momentum and raises concerns about its medium to long-term prospects amid already challenging market conditions.

Orchid Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Orchid Pharma Ltd., a Chennai-headquartered pharmaceutical company with a market capitalisation of ₹3,423.54 crores, has reported deeply concerning results for Q3 FY26 (October-December 2025), posting a consolidated net loss of ₹12.61 crores compared to a profit of ₹20.78 crores in the same quarter last year—a staggering decline of 160.68%. The stock has plummeted 45.83% over the past year, trading at ₹675.00 as of February 12, 2026, down 49.14% from its 52-week high of ₹1,327.15.

Orchid Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 01 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Orchid Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 February 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 21 January 2026, providing investors with the latest perspective on its performance and prospects.

Orchid Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from sideways movement to a mildly bearish trend. Despite some short-term bullish hints, the overall technical landscape suggests caution for investors as the stock grapples with persistent downward pressure.

Orchid Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from a mildly bullish stance to a sideways trend. Despite some short-term bullish cues, the overall technical landscape remains bearish, reflecting ongoing challenges for the pharmaceutical company amid a significant price correction and underperformance relative to the broader market.

Orchid Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.